1. <menuitem id="nbjb9"><p id="nbjb9"></p></menuitem>
      <nav id="nbjb9"><strike id="nbjb9"><bdo id="nbjb9"></bdo></strike></nav>
      1. <s id="nbjb9"><b id="nbjb9"><noscript id="nbjb9"></noscript></b></s>
        

      2. <rt id="nbjb9"><cite id="nbjb9"><samp id="nbjb9"></samp></cite></rt>

        <rt id="nbjb9"><option id="nbjb9"></option></rt>

        CN  /  EN

        imgboxbg

        NEWS

        最新消息

        华讯参展2021云上南京软博会

        • 分类:最新消息
        • 作者:华讯知识产权
        • 来源:
        • 发布时间:2021-12-27 17:03
        • 访问量:

        【概要描述】华讯一直行走在软件信息的专利顾问服务前沿,紧跟软件信息产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国软件信息产业的发展出一份力。

        华讯参展2021云上南京软博会

        【概要描述】华讯一直行走在软件信息的专利顾问服务前沿,紧跟软件信息产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国软件信息产业的发展出一份力。

        • 分类:最新消息
        • 作者:华讯知识产权
        • 来源:
        • 发布时间:2021-12-27 17:03
        • 访问量:
        详情

        2021年12月26日,华讯作为南京市知识产权维权中心江北分中心,入驻此次2021云上南京软博会。

        此次大会以“软件定义,点燃数字引擎”为主题,全称为:2021云上中国(南京)国际软件产品和信息服务交易博览会暨全球软件产业高峰论坛,由江苏省工业和信息化厅、南京市人民政府主办。

        开幕仪式上,南京市委副书记、代市长夏心旻,工业和信息化部信息技术发展司司长谢少锋,江苏省工业和信息化厅副厅长池宇致辞。图灵奖获得者Yoshua Bengio、中国工程院院士高文、加拿大工程院院士杨军和悉尼科技大学副校长张成奇等4名顶尖科学家围绕人工智能、工业软件、产业互联网等方向作主题报告。南瑞集团有限公司董事长、党委书记冷俊,中国航天科工集团二院七〇六所所长袁晓光等2名软件产业领军企业家围绕智能电网、工业软件作主题分享。《南京市推进软件名城提质升级 打造万亿级产业行动计划》在开幕式上正式发布。

        作为首个中国软件名城,南京软件和信息服务产业近年来蓬勃发展,入选国家级先进制造业集群。华讯也一直行走在软件信息的专利顾问服务前沿,紧跟软件信息产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国软件信息产业的发展出一份力。

        关键词:

        Ruige

        Ruige Pharmaceutical's New Generation of CDK2/4/6 Small-molecule Inhibitor Receives FDA Approval for Clinical Research

        Established in 2018, Ruige Pharmaceutical?is committed to the fields of tumors, autoimmunity and metabolism, and develops "first-in-class" and "best-in-class" innovative drugs with independent intellectual property rights. Recently, Ruige Pharmaceutical?announced that its new generation of CDK2/4/6 small- molecule inhibitor RGT-419B has been received FDA approval for clinical research. RGT-419B is a new-generation tumor-targeted inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of currently approved CDK4/6 inhibitors and overcome resistance to these inhibitors. These inhibitors are used in combination with endocrine therapy to treat patients with premenopausal/postmenopausal hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. In cell model experiments, RGT-419B showed single-drug activity, which has a greater inhibitory effect on the growth of estrogen receptor positive (ER+) tumor cells. In ER+ breast cancer cells resistant to currently approved CDK4/6 inhibitors, RGT-419B showed complete inhibition of cancer cell proliferation. In these experiments, when RGT-419B is used in combination with a selective estrogen receptor degrader or PI3K signaling pathway inhibitor, its inhibitory effect on tumor cells is further enhanced. As a single agent and used in combination with other approved therapies, RGT-419B will initially be developed for the treatment of human epidermal growth factor receptor 2 negative (HER2-), ER+ breast cancer patients who have primary or acquired resistance to CDK4/6 inhibitors. With the widespread adoption of CDK4/6 inhibitors in clinical practice, patients with refractory and relapsed patients are becoming larger and clinically significant unmet medical needs. The clinical development project of RGT-419B will solve this resistance to CDK4/6 and other hormone receptor modulating therapies, and provide new opportunities for improving the survival and quality of life of patients with advanced breast cancer. RGT-419B is the first of many innovative oncology drugs being developed by Ruige Pharmaceutical. Founder and CEO Dr. Qiu Xiayang said: "This milestone marks the successful entry of Ruige Pharmaceutical into the field of tumor treatment. We have found the best choice for multiple CDKs through our self-developed AI-assisted new drug development CARD platform. Successfully promoted innovative drugs to enter the clinical development stage in the United States. At the same time, we are very excited that this opportunity can bring new and differentiated treatment options to many breast cancer patients around the world.
        2021-12-30
        台湾华讯入驻台湾国际半导体大会

        台湾华讯入驻台湾国际半导体大会

        此次大会全称为台湾国际半导体展(SEMICON Taiwan 2021)由国际半导体产业协会(SEMI)主办。
        2021-12-28
        华讯参展2021云上南京软博会

        华讯参展2021云上南京软博会

        华讯一直行走在软件信息的专利顾问服务前沿,紧跟软件信息产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国软件信息产业的发展出一份力。
        2021-12-27
        原告被告都是国外企业

        原告被告都是国外企业 他们竟纷纷选择到中国提起诉讼?

        这是一个有趣的趋势:由于种种原因,国外企业纷纷选择在中国提起专利诉讼,起诉非中国企业。
        2021-12-24
        上一页
        1
        2
        ...
        145
        这是描述信息

        江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

        版权所有◎南京华讯知识产权顾问有限公司

        备案号:苏ICP备xxxxxx号-1    网站建设:中企动力 南京

        亚洲AV无码一区二区乱子伦,久久精品中文字幕一区,色费女人18毛片A级毛片视频,欧美+日本+国产+A∨观看